Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146

IF 25.3 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2024-11-01 DOI:10.1016/j.eururo.2024.05.003

Chung-Han Lee , Amishi Yogesh Shah , Arpit Rao , Matthew H. Taylor , Christopher Di Simone , James J. Hsieh , Alvaro Pinto , Regina Gironés Sarrió , Allen Lee Cohn , Mehmet Asim Bilen , Sara Gunnestad Ribe , Øyvind Krohn Tennøe , Donald Richards , Randy F. Sweis , Jay Courtright , Daniel Heinrich , Rodolfo Perini , Peter Kubiak , Daena Bock , Chinyere E. Okpara , Robert J. Motzer

引用次数: 0

查看原文本刊更多论文

转移性透明细胞肾细胞癌患者接受免疫检查点抑制剂治疗后伦伐替尼加 Pembrolizumab：111/KEYNOTE-146研究结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.